● Recruiting

Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study

Condition: Recurrent Ovarian Cancer · Platinum Resistance · Sponsor: The First Hospital of Jilin University

PhaseNA

Planned participants40

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This trial was designed as a single-arm, open-label, prospective clinical trial to evaluate the efficacy (ORR) and safety (AE incidence) of CapsuleX in combination with cisplatin for platinum-resistant recurrent ovarian cancer (PROC).

This description comes directly from the study's public registry record.

Talk to the study team

Zhentong Wei Medic · 15804300686 · zhentongwei2009@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Hospital of Jilin University

Changchun, Jilin, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07495384